Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Aspergillus fumigatus growth
Microbiology Spectrum · 2025
DOI: 10.1128/spectrum.02275-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Elise Biquand und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre d'Étude des Pathologies Respiratoires, Inserm UMR1100, Université de Tours, Tours, France. Hauptthemen laut MEDLINE: Aminophenols, Indoles, Pyrazoles, Pyridines. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Association Vaincre la Mucoviscidose.
Abstract (Originalsprache)
Fungal infection, especially allergic bronchopulmonary aspergillosis, is a leading cause of infection-associated morbidity and death in patients with cystic fibrosis. We have previously discovered that the new leading treatment in cystic fibrosis, CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor (ETI, Trikafta), drastically reduces the colonization and infection by Aspergillus fumigatus . However, the reasons for this decrease in patients are not known so far. In this study, we have shown, using A. fumigatus reference strains and strains isolated from patients with cystic fibrosis, that CFTR modulators have no discernible impact on initial conidia growth in vitro . However, in a condition-dependent manner, we demonstrated a decrease in the minimal effective concentration (MEC) of caspofungin when administered with ETI on conidia. By contrast, during macrophage infection, we observed that high concentrations of ETI treatment promoted fungal growth but inhibited inflammasome activation. IMPORTANCE The advent of ETI therapy represents a pivotal moment, signaling the onset of major changes in the medical field of cystic fibrosis and its related infectious diseases. However, the impact of ETI treatment on the patient’s microbiota and pathogens has to be further studied as proof arises of changes in patient colonization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre d'Étude des Pathologies Respiratoires, Inserm UMR1100, Université de Tours, Tours, France.
- Parasitologie-Mycologie médicale-Médecine tropicale, Pôle Biologie médicale-Pathologie, hôpital Bretonneau, Tours, France.
ORCID-Profile: Elise Biquand, Sandra Khau, Delphine Fouquenet, Samanta Chouela Mbouwe, Floriane Costes, Lucile Drobecq, Adélaïde Chesnay, Guillaume Desoubeaux, Benoit Briard
Förderung
- Association Vaincre la Mucoviscidose
Zitieren
APA
Biquand, E., Khau, S., Fouquenet, D., Chouela Mbouwe, S., Costes, F., Drobecq, L., Chesnay, A., Desoubeaux, G., & Briard, B. (2025). Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Aspergillus fumigatus growth. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02275-24
Vancouver
Biquand E, Khau S, Fouquenet D, Chouela Mbouwe S, Costes F, Drobecq L, et al. Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Aspergillus fumigatus growth. Microbiology Spectrum. 2025. doi:10.1128/spectrum.02275-24
BibTeX
@article{Biquand2025,
author = {Biquand, Elise and Khau, Sandra and Fouquenet, Delphine and Chouela Mbouwe, Samanta and Costes, Floriane and Drobecq, Lucile and Chesnay, Adélaïde and Desoubeaux, Guillaume and Briard, Benoit},
title = {Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Aspergillus fumigatus growth},
journal = {Microbiology Spectrum},
year = {2025},
doi = {10.1128/spectrum.02275-24}
}
EUVIMED